<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="8655a600-ca27-48f4-b4b6-e51a92b88749"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use FILSPARI<sup>®</sup> safely and effectively. See full prescribing information for FILSPARI<sup>®</sup>.<br/>
      <br/>FILSPARI<sup>®</sup> (sparsentan) tablets, for oral use<br/>Initial U.S. Approval: 2023</title>
   <effectiveTime value="20250401"/>
   <setId root="d7354af1-f304-f4d9-e053-2995a90ab219"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="965454502" root="1.3.6.1.4.1.519.1"/>
            <name>Travere Therapeutics, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="965454502" root="1.3.6.1.4.1.519.1"/>
                  <name>Travere Therapeutics, Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="965454502" root="1.3.6.1.4.1.519.1"/>
                        <name>Travere Therapeutics, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68974-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68974-400" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="962674474"/>
                        <name>Catalent CTS, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68974-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68974-400" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3df54a8d-9ef8-4d8b-8aca-0a13699fb8c1"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250401"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68974-200" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>FILSPARI</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>sparsentan</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="200" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9242RO5URM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SPARSENTAN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9242RO5URM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SPARSENTAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H8AV0SQX4D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68974-200-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230217"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216403" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230217"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">105</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="13" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68974-400" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>FILSPARI</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>sparsentan</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="400" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9242RO5URM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SPARSENTAN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9242RO5URM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SPARSENTAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H8AV0SQX4D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68974-400-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230217"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216403" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230217"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">021</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_0">
               <id root="6d0dd9ca-9335-48dd-9455-6031b0e48736"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="bold">WARNING: HEPATOTOXICITY and EMBRYO-FETAL TOXICITY</content>
               </title>
               <text>
                  <paragraph ID="p1259276861662579726">
                     <content styleCode="bold">Because of the risks of hepatotoxicity and birth defects, FILSPARI is available only through a restricted program called the FILSPARI REMS. Under the FILSPARI REMS, prescribers, patients, and pharmacies must enroll in the program <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>, <linkHtml href="#Section_5.2">5.2</linkHtml>, <linkHtml href="#Section_5.3">5.3</linkHtml>)]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <content styleCode="underline">Hepatotoxicity</content>
                        </content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                Some Endothelin Receptor Antagonists (ERAs) have caused elevations of aminotransferases, hepatotoxicity, and liver failure. In clinical studies, elevations in aminotransferases (ALT or AST) of at least 3-times the Upper Limit of Normal (ULN) have been observed in up to 3.5% of FILSPARI-treated patients, including cases confirmed with rechallenge.
              </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Measure transaminases and bilirubin before initiating treatment and monthly for the first 12 months, and then every 3 months during treatment. Interrupt treatment and closely monitor patients who develop aminotransferase elevations more than 3-times ULN </content>
                     <content styleCode="bold">
                        <content styleCode="italics">[see Dosage and Administration</content>
                        <content styleCode="italics"> (<linkHtml href="#Section_2.3">2.3</linkHtml>
                        </content>
                        <content styleCode="italics">, <linkHtml href="#Section_2.5">2.5</linkHtml>), Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>.</content>
                  </paragraph>
                  <paragraph ID="p4246861662579785">
                     <content styleCode="bold">FILSPARI should generally be avoided in patients with elevated aminotransferases (&gt;3-times ULN) at baseline because monitoring for hepatotoxicity may be more difficult and these patients may be at increased risk for serious hepatotoxicity <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.3">2.3</linkHtml>, <linkHtml href="#Section_2.5">2.5</linkHtml>), Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)].</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">
                        <content styleCode="bold">
                           <content styleCode="italics">Embryo-Fetal Toxicity</content>
                        </content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FILSPARI can cause major birth defects if used by pregnant patients based on animal data <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>), Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>)]</content>. Therefore, pregnancy testing is required before the initiation of treatment, during treatment, and one month after discontinuation of treatment with FILSPARI. Patients who can become pregnant must use effective contraception before the initiation of treatment, during treatment, and for one month after discontinuation of treatment with FILSPARI <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>), Contraindications (<linkHtml href="#Section_4">4</linkHtml>), Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>), Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.3">8.3</linkHtml>)]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="P2">WARNING: HEPATOTOXICITY and EMBRYO-FETAL TOXICITY</paragraph>
                        <paragraph ID="P3">
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>FILSPARI is only available through a restricted distribution program called the FILSPARI Risk Evaluation and Mitigation Strategies (REMS) because of these risks (<linkHtml href="#Section_5.3">5.3</linkHtml>):</item>
                           <item>Some endothelin receptor antagonists have caused elevations of aminotransferases, hepatotoxicity, and liver failure (<linkHtml href="#Section_5.1">5.1</linkHtml>).</item>
                           <item>Measure liver aminotransferases and total bilirubin prior to initiation of treatment and ALT and AST monthly for 12 months, then every 3 months during treatment (<linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_2.5">2.5</linkHtml>, <linkHtml href="#Section_5.1">5.1</linkHtml>).</item>
                           <item>Interrupt treatment and closely monitor patients developing aminotransferase elevations more than 3-times Upper Limit of Normal (ULN) (<linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_2.5">2.5</linkHtml>).</item>
                           <item>Based on animal data, FILSPARI can cause major birth defects if used during pregnancy (<linkHtml href="#Section_4">4</linkHtml>, <linkHtml href="#Section_5.2">5.2</linkHtml>, <linkHtml href="#Section_8.1">8.1</linkHtml>).</item>
                           <item>Pregnancy testing is required before, during, and after treatment (<linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_4">4</linkHtml>, <linkHtml href="#Section_5.2">5.2</linkHtml>, <linkHtml href="#Section_8.1">8.1</linkHtml>).</item>
                           <item>Patients who can become pregnant must use effective contraception prior to initiation of treatment, during treatment, and for one month after (<linkHtml href="#Section_4">4</linkHtml>, <linkHtml href="#Section_5.2">5.2</linkHtml>, <linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.3">8.3</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L8f470736-d3bf-40de-ac45-e8590b6f0e47">
               <id root="8ab4913e-18c9-443f-adf8-ddab5761b5d2"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <text/>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <caption/>
                           <tbody>
                              <tr styleCode="First Last">
                                 <td>
                                    <list listType="unordered">
                                       <item>Indications and Usage </item>
                                    </list>
                                 </td>
                                 <td> 9/2024</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="4c2c6b10-c20e-45f3-ad59-665618d30d5a"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1  INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="P5">
                     <content styleCode="xmChange">FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p41113301644346247">FILSPARI is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression (<linkHtml href="#Section_1">1</linkHtml>, <linkHtml href="#Section_12.1">12.1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="e883987f-6d0f-4e20-aeb0-6222e70783c2"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2  DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Prior to initiating treatment with FILSPARI, discontinue use of renin- angiotensin-aldosterone system (RAAS) inhibitors and endothelin receptor antagonists (ERAs) (<linkHtml href="#Section_2.1">2.1</linkHtml>, <linkHtml href="#Section_4">4</linkHtml>, <linkHtml href="#Section_7.1">7.1</linkHtml>).</item>
                           <item>Initiate treatment with FILSPARI at 200 mg orally once daily. After 14 days, increase to 400 mg once daily, as tolerated. When resuming FILSPARI after an interruption, consider re-titration (<linkHtml href="#Section_2.3">2.3</linkHtml>).</item>
                           <item>Instruct patients to swallow tablets whole with water prior to the morning or evening meal (<linkHtml href="#Section_2.4">2.4</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="498ae9a3-4328-4f0e-a863-db5922825ccb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1  General Considerations </title>
                     <text>
                        <paragraph ID="p64170301644347727">Prior to initiating treatment with FILSPARI, discontinue use of renin-angiotensin-aldosterone system (RAAS) inhibitors and endothelin receptor antagonists (ERAs) <content styleCode="italics">[see Contraindications (<linkHtml href="#Section_4">4</linkHtml>), Drug Interactions (<linkHtml href="#Section_7.1">7.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="f5ab792c-362b-4734-b05c-3fce273ef7e2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2  Monitoring</title>
                     <text>
                        <paragraph ID="p669612301644347732">Initiate treatment with FILSPARI only after measuring aminotransferase levels and total bilirubin. Avoid initiation in patients with elevated aminotransferases greater than 3 times ULN. Continue required monitoring monthly for the first 12 months after initiation or restarting following an interruption due to elevated transaminases, then every 3 months during treatment with FILSPARI <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.3">2.3</linkHtml>, <linkHtml href="#Section_2.5">2.5</linkHtml>), Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <br/>Initiate treatment with FILSPARI in patients who can become pregnant only after confirmation of a negative pregnancy test. Pregnancy tests are required monthly during treatment and one month after discontinuation of treatment with FILSPARI <content styleCode="italics">[</content>see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>), Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#undefined">8.3</linkHtml>)<content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="92f89ca4-bce4-49ea-9996-988041886874"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3  Recommended Dosage</title>
                     <text>
                        <paragraph ID="p669912301644347739">Initiate treatment with FILSPARI at 200 mg orally once daily. After 14 days, increase to the recommended dose of 400 mg once daily, as tolerated. When resuming treatment with FILSPARI after an interruption, consider titration of FILSPARI, starting at 200 mg once daily. After 14 days, increase to the recommended dose of 400 mg once daily <content styleCode="italics">[see Drug Interactions (7.2)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.4">
                     <id root="c04e5c81-1240-45b6-a5ca-34ba11b4b173"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4  Administraion</title>
                     <text>
                        <list listType="unordered">
                           <item>Instruct patient to swallow tablets whole with water prior to the morning or evening meal.</item>
                           <item>Maintain the same dosing pattern in relationship to meals.</item>
                           <item>If a dose is missed, take the next dose at the regularly scheduled time. Do not take double or extra doses.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.5">
                     <id root="df54cc3d-f14a-4a96-b31e-7e572efed5d4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5  Dosage Adjustment for Aminotransferase Elevations</title>
                     <text>
                        <paragraph ID="p670212341644345742">If aminotransferase levels increase, adjust monitoring and treatment plan according to <linkHtml href="#table1">Table 1</linkHtml>.</paragraph>
                        <paragraph>Do not resume treatment in patients who have experienced clinical symptoms of hepatotoxicity or in patients whose hepatic enzyme levels and bilirubin have not returned to pretreatment levels.</paragraph>
                        <table ID="table1" width="100%">
                           <caption>Table 1: Dosage Adjustment and Monitoring in Patients Developing Aminotransferase Elevations Greater Than 3 Times ULN</caption>
                           <colgroup>
                              <col width="20%"/>
                              <col width="80%"/>
                           </colgroup>
                           <tfoot>
                              <tr styleCode="First FIRST Last LAST">
                                 <td colspan="3">ALT = alanine aminotransferase; AST = aspartate aminotransferase; INR = international normalized ratio; ULN = upper limit of normal.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">ALT/AST levels</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Treatment and monitoring recommendations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Greater than 3 times and less than or equal to 8 times ULN</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <paragraph>Confirm elevation with a repeat measure.</paragraph>
                                    <br/>
                                    <paragraph>If confirmed, interrupt treatment, and monitor aminotransferase levels and bilirubin at least weekly, and INR as needed, until the levels return to pretreatment values and the patient is asymptomatic.</paragraph>
                                    <paragraph>Do not resume treatment if any of the following occurs without other cause found:</paragraph>
                                    <list listType="unordered">
                                       <item>ALT or AST greater than 3 times ULN and total bilirubin greater than 2 times ULN or INR greater than 1.5</item>
                                       <item>ALT or AST greater than 3 times ULN, with symptoms of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (greater than 5% eosinophils)</item>
                                       <item>ALT or AST greater than 5 times ULN for more than 2 weeks</item>
                                    </list>
                                    <paragraph>If treatment is resumed, initiate FILSPARI at 200 mg once daily, with reassessment of hepatic enzyme levels and bilirubin within 3 days. Close monitoring is required in these patients <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_2.3">2.3</linkHtml>
                                          <linkHtml href="#Section_2.4">)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Greater than 8 times ULN</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Stop treatment permanently if no other cause found.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="L1d2f76fc-5673-415b-9684-d75bbc89b0b8">
                     <id root="f5afd1c0-2fcb-405e-9517-7c5cda7f4b33"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6  Dosage Modification for Concomitant Use with Strong CYP3A Inhibitors</title>
                     <text>
                        <paragraph ID="p670512301644347751">Avoid concomitant use of strong CYP3A inhibitors with FILSPARI.</paragraph>
                        <paragraph ID="p69145301644347772">If a strong CYP3A inhibitor cannot be avoided, interrupt treatment with FILSPARI <content styleCode="italics">[see Drug Interactions (<linkHtml href="#Section_7.2">7.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="1a69e6c3-5abf-407b-b161-7802621b6fea"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3  DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>FILSPARI is supplied as film-coated, modified oval, white to off-white tablets debossed on one side and plain on the other in the following strengths:</paragraph>
                  <paragraph>      200 mg debossed with “105”<br/>      400 mg debossed with “021”</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="s3highlight">Tablets: 200 mg and 400 mg (<linkHtml href="#Section_3">3</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="31440f7b-6c9d-414d-a391-53da18d0421b"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4  CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="p13588116861662580971">Use of FILSPARI is contraindicated in patients who are pregnant <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>), Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>), Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p13866116861662580978">Do not coadminister FILSPARI with ARBs, ERAs, or aliskiren <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.1">2.1</linkHtml>), Drug Interactions (<linkHtml href="#Section_7.1">7.1</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Pregnancy (<linkHtml href="#Section_4">4</linkHtml>).</item>
                           <item>Concomitant use with angiotensin receptor blockers (ARBs), ERAs, or aliskiren (<linkHtml href="#Section_4">4</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="3622515a-944b-4c27-a2c5-32bdb51de88d"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5  WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Hypotension (<linkHtml href="#Section_5.4">5.4</linkHtml>
                              <content>)</content>
                           </item>
                           <item>Acute Kidney Injury (<linkHtml href="#Section_5.5">5.5</linkHtml>
                              <content>)</content>
                           </item>
                           <item>Hyperkalemia (<linkHtml href="#Section_5.6">5.6</linkHtml>
                              <content>)</content>
                           </item>
                           <item>Fluid Retention (<linkHtml href="#Section_5.7">5.7</linkHtml>
                              <content>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="0411d670-2575-47f1-ae05-d54a4790cac6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1  Hepatotoxicity</title>
                     <text>
                        <paragraph ID="p13611216861662581059">.Elevations in ALT or AST of at least 3-fold ULN have been observed in up to 3.5% of FILSPARI-treated patients, including cases confirmed with rechallenge <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)].</content> While no concurrent elevations in bilirubin greater than 2-times ULN or cases of liver failure were observed in FILSPARI-treated patients in clinical trials, some endothelin receptor antagonists have caused elevations of aminotransferases, hepatotoxicity, and liver failure. To reduce the risk of potential serious hepatotoxicity, measure serum aminotransferase levels and total bilirubin prior to initiation of treatment and monthly for the first 12 months, then every 3 months during treatment <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Advise patients with symptoms suggesting hepatotoxicity (nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, or itching) to immediately stop treatment with FILSPARI and seek medical attention. If aminotransferase levels are abnormal at any time during treatment, interrupt FILSPARI and monitor as recommended <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.5">2.5</linkHtml>)]</content>.</paragraph>
                        <paragraph>Consider re-initiation of FILSPARI only when hepatic enzyme levels and bilirubin return to pretreatment values and only in patients who have not experienced clinical symptoms of hepatotoxicity <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_2.5">2.5</linkHtml>)]</content>.</paragraph>
                        <paragraph>Avoid initiation of FILSPARI in patients with elevated aminotransferases (greater than 3-times ULN) prior to drug initiation because monitoring hepatotoxicity in these patients may be more difficult and these patients may be at increased risk for serious hepatotoxicity <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_2.5">2.5</linkHtml>), and Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="4cc0bae6-5c5f-4d9c-8a49-db8b49fc6d6d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2  Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph ID="p13651116861662581551">Based on data from animal reproduction studies, FILSPARI can cause fetal harm when administered to a pregnant patient and is contraindicated during pregnancy. Advise patients who can become pregnant of the potential risk to a fetus. Obtain a pregnancy test prior to initiation of treatment with FILSPARI, monthly during treatment, and one month after discontinuation of treatment. Advise patients who can become pregnant to use effective contraception prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with FILSPARI <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>), Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>) and Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.3">8.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="620c16e3-9e78-47c9-bfe8-712dca4e7359"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3  FILSPARI REMS</title>
                     <text>
                        <paragraph ID="p82107301644366839">For all patients, FILSPARI is available only through a restricted program under a REMS called the FILSPARI REMS because of the risk of hepatotoxicity and embryo-fetal toxicity <content styleCode="italics">[see Contraindications (<linkHtml href="#Section_4">4</linkHtml>), Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>, <linkHtml href="#Section_5.2">5.2</linkHtml>), Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.3">8.3</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p82137301644366847">Important requirements of the FILSPARI REMS include the following:</paragraph>
                        <list listType="unordered" ID="l82187301644366854" styleCode="Disc">
                           <item>Prescribers must be certified with the FILSPARI REMS by enrolling and completing training.</item>
                           <item>All patients must enroll in the FILSPARI REMS prior to initiating treatment and comply with monitoring requirements <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_2.5">2.5</linkHtml>), Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>, <linkHtml href="#Section_5.2">5.2</linkHtml>), Use in Specific Populations (<linkHtml href="#Section_8.3">8.3</linkHtml>)]</content>.</item>
                           <item>Pharmacies that dispense FILSPARI must be certified with the FILSPARI REMS and must dispense only to patients who are authorized to receive FILSPARI.</item>
                        </list>
                        <paragraph ID="p84882301644366893">Further information is available at www.filsparirems.com or 1-833-513-1325.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="a4907713-732f-49c0-9c10-0ec017f95d52"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4  Hypotension</title>
                     <text>
                        <paragraph ID="p87421301644367462">Hypotension has been observed in patients treated with ARBs and endothelin receptor antagonists (ERAs) and was observed in clinical studies with FILSPARI. In the PROTECT trial, there was a greater incidence of hypotension-associated adverse events, some serious, including dizziness, in patients treated with FILSPARI compared to irbesartan<content styleCode="italics"> [see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p87451301644367475">In patients at risk for hypotension, consider eliminating or adjusting other antihypertensive medications and maintaining appropriate volume status.</paragraph>
                        <paragraph ID="p87481301644367482">If hypotension develops, despite elimination or reduction of other antihypertensive medications, consider a dose reduction or dose interruption of FILSPARI. A transient hypotensive response is not a contraindication to further dosing of FILSPARI, which can be given once blood pressure has stabilized.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="788631ce-9c84-40fa-be66-a7e01b5af58a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5  Acute Kidney Injury</title>
                     <text>
                        <paragraph ID="p87511301644367496">Monitor kidney function periodically. Drugs that inhibit the renin-angiotensin system can cause acute kidney injury. Patients whose kidney function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute kidney injury on FILSPARI. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in kidney function while on FILSPARI.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="d6c459c8-825a-4450-b19c-97e95b0db61a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6  Hyperkalemia</title>
                     <text>
                        <paragraph ID="p14874106861662581597">Monitor serum potassium periodically and treat appropriately. Patients with advanced kidney disease or taking concomitant potassium-increasing drugs (e.g., potassium supplements, potassium-sparing diuretics), or using potassium-containing salt substitutes are at increased risk for developing hyperkalemia. Dosage reduction or discontinuation of FILSPARI may be required<content styleCode="italics"> [see Dosage and Administration (<linkHtml href="#Section_2.3">2.3</linkHtml>), Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="c4407fdf-d897-427b-ba63-1f747aa4f061"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7  Fluid Retention</title>
                     <text>
                        <paragraph ID="p89931301644367594">Fluid retention may occur with endothelin receptor antagonists and has been observed in clinical studies with FILSPARI <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)]</content>. FILSPARI has not been evaluated in patients with heart failure.</paragraph>
                        <paragraph ID="p307536861662581658">If clinically significant fluid retention develops, evaluate the patient to determine the cause and the potential need to initiate or modify the dose of diuretic treatment then consider modifying the dose of FILSPARI.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="cfdfe5a2-4d22-4d8b-9eb2-a66bc7f042c8"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6  ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="P10">Clinically significant adverse reactions that appear in other sections of the label include:</paragraph>
                  <list listType="unordered">
                     <item>Hepatotoxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>
                     </item>
                     <item>Embryo-Fetal Toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>
                     </item>
                     <item>Hypotension <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)]</content>
                     </item>
                     <item>Acute Kidney Injury<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#Section_5.5">5.5</linkHtml>)]</content>
                     </item>
                     <item>Hyperkalemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.6">5.6</linkHtml>)]</content>
                     </item>
                     <item>Fluid Retention <content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#Section_5.7">5.7</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (≥5%) are hyperkalemia, hypotension (including orthostatic hypotension), peripheral edema, dizziness, anemia, and acute kidney injury (<linkHtml href="#Section_6.1">6.1</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Travere Therapeutics at 1-877-659-5518 or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="ed23e38e-128a-4ede-a112-6b76f4d07141"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1  Clinical Trials
Experience</title>
                     <text>
                        <paragraph ID="p97496301644367759">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph ID="p974515301644367789">The safety of FILSPARI was evaluated in PROTECT (<linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT03762850">NCT03762850</linkHtml>), a randomized, double-blind, active-controlled clinical study in adults with IgAN.</paragraph>
                        <paragraph ID="p97621301644367795">The data below reflect FILSPARI exposure in 202 patients with a median duration of 110 weeks.</paragraph>
                        <paragraph ID="p97650301644367811">The most common adverse reactions are presented in <linkHtml href="#table2">Table 2</linkHtml>.</paragraph>
                        <table ID="table2" width="100%">
                           <caption>Table 2: Adverse Reactions Reported in 2% or More of Subjects Treated with FILSPARI</caption>
                           <colgroup>
                              <col/>
                              <col/>
                              <col/>
                           </colgroup>
                           <tfoot>
                              <tr styleCode="First FIRST Last LAST">
                                 <td colspan="3">
                                    <sup>1</sup> Includes related terms.<br/>
                                    <sup>2</sup> Elevations in ALT or AST greater than 3-fold ULN. </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top"/>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">FILSPARI<br/>(N = 202)<br/>n (%)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Irbesartan<br/>(N = 202)<br/>n (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"> Hyperkalemia<sup>1</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">34 (17)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">27 (13)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"> Hypotension (including orthostatic hypotension)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">33 (16)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">13 (6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"> Peripheral edema<sup>1</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">33 (16)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">29 (14)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"> Dizziness<sup>1</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">32 (16)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">14 (7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"> Anemia</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">16 (8)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">9 (4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"> Acute kidney injury</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">12 (6)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">5 (2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"> Transaminase elevations<sup>2</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">7 (3.5)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">8 (4.0)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p462436861662582130">
                           <content styleCode="underline">Laboratory Tests</content>
                        </paragraph>
                        <paragraph>Initiation of FILSPARI may cause an initial small decrease in estimated glomerular filtration rate (eGFR) that occurs within the first 4 weeks of starting therapy and then stabilizes.</paragraph>
                        <paragraph>The incidence of a hemoglobin decrease &gt;2 g/dL compared to baseline and below the lower limit of normal was greater for the FILSPARI arm (19%) compared to the irbesartan arm (13%). This decrease is thought to be in part due to hemodilution. There were no treatment discontinuations due to anemia or hemoglobin decrease in the PROTECT study.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="aec0605d-d86c-4c58-bc24-8a458345dfc9"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7  DRUG INTERACTIONS</title>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Strong CYP3A inhibitors: Avoid concomitant use. Increased sparsentan exposure (<linkHtml href="#Section_2.5">2.6</linkHtml>, <linkHtml href="#Section_7.2">7.2</linkHtml>, <linkHtml href="#Section_12.3">12.3</linkHtml>).</item>
                           <item>Moderate CYP3A inhibitors: Monitor adverse reactions. Increased sparsentan exposure (<linkHtml href="#Section_7.2">7.2</linkHtml>, <linkHtml href="#Section_12.3">12.3</linkHtml>).</item>
                           <item>Strong CYP3A inducers: Avoid concomitant use. Decreased sparsentan exposure (<linkHtml href="#Section_7.3">7.3</linkHtml>, <linkHtml href="#Section_12.3">12.3</linkHtml>).</item>
                           <item>Antacids: Avoid use within 2 hours before or after use of sparsentan. May decrease exposure to sparsentan (<linkHtml href="#Section_7.4">7.4</linkHtml>, <linkHtml href="#Section_11">11</linkHtml>).</item>
                           <item>Acid reducing agents: Avoid concomitant use. May decrease exposure to sparsentan (<linkHtml href="#Section_7.4">7.4</linkHtml>).</item>
                           <item>Non-steroidal anti-inflammatory drugs (NSAIDs) including selective cyclooxygenase (COX-2) inhibitors: Monitor for signs of worsening renal function. Increased risk of kidney injury (<linkHtml href="#Section_7.5">7.5</linkHtml>).</item>
                           <item>CYP2B6, 2C9, and 2C19 substrates: Monitor for substrate efficacy. Decreased exposure of these substrates (<linkHtml href="#Section_7.6">7.6</linkHtml>, <linkHtml href="#Section_12.3">12.3</linkHtml>).</item>
                           <item>Sensitive P-gp and BCRP substrates: Avoid concomitant use. Increased exposure to substrates (<linkHtml href="#Section_7.7">7.7</linkHtml>, <linkHtml href="#Section_12.3">12.3</linkHtml>).</item>
                           <item>Agents Increasing Serum Potassium: Increased risk of hyperkalemia, monitor serum potassium frequently (<linkHtml href="#Section_5.6">5.6</linkHtml>, <linkHtml href="#L5cf3356d-3a39-4821-993b-c5eaf534060d">7.8</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="7374763f-9882-433f-970b-0d01fc974cee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1  Renin-Angiotensin System Inhibitors and ERAs</title>
                     <text>
                        <paragraph ID="p1843366861662582227">Do not coadminister FILSPARI with ARBs, ERAs, or aliskiren <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.1">2.1</linkHtml>), Contraindications (<linkHtml href="#Section_4">4</linkHtml>)]</content>.</paragraph>
                        <paragraph>Combined use of these agents is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure).</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.2">
                     <id root="b6b9ec7b-38a7-41ba-862c-12f1d0d6925a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2  Strong and Moderate CYP3A Inhibitors</title>
                     <text>
                        <paragraph>Avoid concomitant use of FILSPARI with strong CYP3A inhibitors. If a strong CYP3A inhibitor cannot be avoided, interrupt treatment with FILSPARI. When resuming treatment with FILSPARI, consider dose titration <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.3">2.3</linkHtml>, <linkHtml href="#Section_2.5">2.6</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>Monitor blood pressure, serum potassium, edema, and kidney function regularly when used concomitantly with moderate CYP3A inhibitors <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>, <linkHtml href="#Section_5.5">5.5</linkHtml>, <linkHtml href="#Section_5.6">5.6</linkHtml>, <linkHtml href="#Section_5.7">5.7</linkHtml>)]</content>. No FILSPARI dose adjustment is needed.</paragraph>
                        <paragraph>Sparsentan is a CYP3A substrate. Concomitant use with a strong CYP3A inhibitor increases sparsentan C<sub>max</sub> and AUC <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>, which may increase the risk of FILSPARI adverse reactions.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.3">
                     <id root="23238c70-d0d8-4818-9524-7e4b0234a3ad"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3  Strong CYP3A Inducers</title>
                     <text>
                        <paragraph>Avoid concomitant use with a strong CYP3A inducer. Sparsentan is a CYP3A substrate. Concomitant use with a strong CYP3A inducer decreases sparsentan C<sub>max</sub> and AUC <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>, which may reduce FILSPARI efficacy.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.4">
                     <id root="6ed135e7-2fff-4567-b3c0-6b7a07dd179f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4  Antacids and Acid Reducing Agents</title>
                     <text>
                        <paragraph>Administer FILSPARI 2 hours before or after administration of antacids. Avoid concomitant use of acid reducing agents (histamine H2 receptor antagonist and PPI proton pump inhibitor) with FILSPARI. Sparsentan exhibits pH-dependent solubility <content styleCode="italics">[see Description (<linkHtml href="#Section_11">11</linkHtml>)]</content>. Antacids or acid reducing agents may decrease sparsentan exposure which may reduce FILSPARI efficacy.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.5">
                     <id root="cad7ce82-455d-4e53-b0ed-3212d49ac498"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5  Non-Steroidal Anti-Inflammatory Agents (NSAIDs), Including Selective Cyclooxygenase-2 (COX-2) Inhibitors</title>
                     <text>
                        <paragraph>Monitor for signs of worsening renal function with concomitant use with NSAIDs (including selective COX-2 inhibitors). In patients with volume depletion (including those on diuretic therapy) or with impaired kidney function, concomitant use of NSAIDs (including selective COX-2 inhibitors) with drugs that antagonize the angiotensin II receptor may result in deterioration of kidney function, including possible kidney failure <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.5">5.5</linkHtml>)]</content>. These effects are usually reversible.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.6">
                     <id root="5563f220-63bf-4b03-97cc-81928de1c192"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6  CYP2B6, 2C9, and 2C19 Substrates</title>
                     <text>
                        <paragraph>Monitor for efficacy of the concurrently administered CYP2B6, 2C9, and 2C19 substrates and consider dosage adjustment in accordance with the Prescribing Information. Sparsentan is an inducer of CYP2B6, 2C9, and 2C19. Sparsentan decreases exposure of these substrates <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>, which may reduce efficacy related to these substrates.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.7">
                     <id root="e3bb9c89-42f6-4978-8f12-18f9a47b5f09"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.7  P-gp and BCRP Substrates</title>
                     <text>
                        <paragraph>Avoid concomitant use of sensitive substrates of P-gp and BCRP with FILSPARI. Sparsentan is an inhibitor of P-gp and BCRP. Sparsentan may increase exposure of these transporter substrates <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>, which may increase the risk of adverse reactions related to these substrates.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.8">
                     <id root="2df3fc5f-66d4-4944-bd22-05b89113e576"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.8  Agents Increasing Serum Potassium</title>
                     <text>
                        <paragraph>Monitor serum potassium frequently in patients treated with FILSPARI and other agents that increase serum potassium. Concomitant use of FILSPARI with potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes, or other drugs that raise serum potassium levels may result in hyperkalemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.6">5.6</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="10209815-9827-4dc4-817d-429e782b396c"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8  USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Lactation: Advise not to breastfeed (<linkHtml href="#Section_8.2">8.2</linkHtml>).</item>
                        </list>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="c91ad170-dfa3-43e3-acd4-8ef81e5e8516"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1  Pregnancy</title>
                     <text>
                        <paragraph ID="p1230112301644373649">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph ID="p123205301644373655">Based on data from animal reproductive toxicity studies, FILSPARI can cause fetal harm, including birth defects and fetal death, when administered to a pregnant patient and is contraindicated during pregnancy <content styleCode="italics">[see Contraindications (<linkHtml href="#Section_4">4</linkHtml>)]</content>. Available data from reports of pregnancy in clinical trials with FILSPARI are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of sparsentan to pregnant rats throughout organogenesis at 10-times the maximum recommended human dose (MRHD) in mg/day caused teratogenic effects in rats, including craniofacial malformations, skeletal abnormalities, increased embryo-fetal lethality, and reduced fetal weights <content styleCode="italics">(see Data)</content>. Advise pregnant patients of the potential risk to the fetus.</paragraph>
                        <paragraph ID="p123235301644373666">The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                        <paragraph ID="p123265301644373710">
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph ID="p123295301644373716">Animal Data</paragraph>
                        <paragraph ID="p123325301644373722">In embryo-fetal development studies in pregnant rats and rabbits, teratogenicity and/or developmental toxicity were observed, which were attributed to the antagonism of endothelin type A (ET<sub>A</sub>) and angiotensin II type 1 (AT<sub>1</sub>) receptors.</paragraph>
                        <paragraph ID="p1438076861662604605">In pregnant rats, oral administration of sparsentan throughout organogenesis at doses of 80, 160, and 240 mg/kg/day resulted in dose-dependent teratogenic effects in the form of craniofacial malformations, skeletal abnormalities, increased embryo-fetal lethality, and reduced fetal weights at all doses tested. The area under the curve (AUC) at the lowest dose tested (80 mg/kg/day) was approximately 10 times the AUC at the MRHD of 400 mg/day. In pregnant rabbits, oral administration of sparsentan throughout organogenesis at doses of 2.5, 10 and 40 mg/kg/day resulted in maternal death and abortions at 10 and 40 mg/kg/day which provided exposures approximately 0.1 times and 0.2 times the AUC at the MRHD, respectively. An increase in a fetal variation (supernumerary cervical ribs) occurred at the high dose of 40 mg/kg/day.</paragraph>
                        <paragraph ID="p565736861662604613">In the pre- and postnatal development study in rats, oral administration of sparsentan during pregnancy and the lactational period at doses of 5, 20, or 80 mg/kg/day resulted in maternal death, body weight loss/reduced body weight gain, and adverse clinical signs at 80 mg/kg/day. An increase in pup deaths occurred at 80 mg/kg/day (approximately 10 times the AUC at MRHD) during the neonatal period through weaning, and decreased growth occurred at ≥ 20 mg/kg/day (approximately 2.6 times the AUC at the MRHD) after weaning. The NOAEL for pre- and postnatal development in rats was 5 mg/kg/day, approximately 0.7 times the AUC at the MRHD.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="90392e69-c6af-431b-b843-9f96f4accb5c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2  Lactation</title>
                     <text>
                        <paragraph ID="p123108301644374279">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph ID="p125931301644374286">There are no data on the presence of sparsentan in human milk, the effects on the breastfed infant, or the effect on milk production. Because of the potential for adverse reactions, such as hypotension in breastfed infants, advise patients not to breastfeed during treatment with FILSPARI.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.3">
                     <id root="45295ed0-69dd-4318-ac04-d4f30c1e942b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.3  Females and Males
of Reproductive Potential</title>
                     <text>
                        <paragraph ID="p16400136861662604700">Based on data from animal reproductive toxicity studies, FILSPARI can cause fetal harm, including birth defects and fetal death, when administered to a pregnant patient and is contraindicated during pregnancy <content styleCode="italics">[see Contraindications (<linkHtml href="#Section_4">4</linkHtml>), Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p128022301644374293">
                           <content styleCode="underline">Pregnancy Testing</content>
                           <br/>Verify that patients who can become pregnant are not pregnant prior to initiating FILSPARI, monthly during treatment, and one month after discontinuation of treatment. The patient should contact their physician immediately for pregnancy testing if onset of menses is delayed or pregnancy is suspected. If the pregnancy test is positive, the physician and patient must discuss the risks to their pregnancy and the fetus.</paragraph>
                        <paragraph ID="p128392301644374713">
                           <content styleCode="underline">Contraception</content>
                           <br/>Patients who can become pregnant who are using FILSPARI must use an effective method of contraception prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with FILSPARI to prevent pregnancy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="a12a5dbd-9284-4f14-b1c9-351a707a1c2c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4  Pediatric Use </title>
                     <text>
                        <paragraph ID="p128362301644374509">The safety and efficacy of FILSPARI in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="86f9cb81-f015-4b2a-a4f4-a5b873a8cd21"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5  Geriatric Use</title>
                     <text>
                        <paragraph ID="p130611301644374796">Of the total number of subjects in the PROTECT study of FILSPARI, 15 (7.4%) were 65 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="3a1f2b4b-b37b-4650-a11f-9b05878141cb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6  Hepatic Impairment</title>
                     <text>
                        <paragraph>Avoid use of FILSPARI in patients with any hepatic impairment (Child-Pugh class A-C) because of the potential risk of serious liver injury <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="135c69a4-aed9-4649-af0f-89a00b026ec1"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10  OVERDOSAGE</title>
               <text>
                  <paragraph ID="P24">There is no experience with overdose with FILSPARI. Sparsentan has been given in doses up to 1600 mg/day in healthy volunteers, or up to 400 mg/day in IgAN patients. Overdose of FILSPARI may result in decreased blood pressure. In the event of an overdose, standard supportive measures should be taken, as required. Dialysis is unlikely to be effective because sparsentan is highly protein-bound.</paragraph>
               </text>
               <effectiveTime value="20250401"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="74374600-8c4c-4d13-bcd7-df65dd8a9e79"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11  DESCRIPTION</title>
               <text>
                  <paragraph ID="P25">FILSPARI (sparsentan) is an endothelin and angiotensin II receptor antagonist. The chemical name of sparsentan is 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide.</paragraph>
                  <paragraph ID="p8034301644374946">Sparsentan is a white to off-white powder, which is practically insoluble in water. Sparsentan has pH-dependent solubility, with intrinsic solubility of 1.48 and 0.055 mg/mL under pH 1.2 and 6.8, respectively. Sparsentan has a molecular weight of 592.76 g/mol, a molecular formula of C<sub>32</sub>H<sub>40</sub>N<sub>4</sub>O<sub>5</sub>S, and the following structure:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="g8115301644375115"/>
                  </paragraph>
                  <paragraph ID="p8064301644374954">FILSPARI is available as film-coated 200 mg and 400 mg strength immediate release tablets for oral administration.</paragraph>
                  <paragraph ID="p615546861662604932">The inactive ingredients in FILSPARI are colloidal silicon dioxide, lactose anhydrous, magnesium stearate, silicified microcrystalline cellulose, and sodium starch glycolate. Film-coating is composed of macrogol/polyethylene glycol, polyvinyl alcohol-partially hydrolyzed, talc, and titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="g8115301644375115">
                     <text>Sparsentan Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sparsentan_structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="7195f518-5aa6-4c81-bbbf-fa4759fdf9bf"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12  CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250401"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="665bd251-2961-43ba-9362-b43b2ce1f8fb"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1  Mechanism of Action</title>
                     <text>
                        <paragraph ID="P27">Sparsentan is a single molecule with antagonism of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II type 1 receptor (AT<sub>1</sub>R). Sparsentan has high affinity for both the ET<sub>A</sub>R (Ki= 12.8 nM) and the AT<sub>1</sub>R (Ki=0.36 nM), and greater than 500-fold selectivity for these receptors over the endothelin type B and angiotensin II subtype 2 receptors. Endothelin 1 and angiotensin II are thought to contribute to the pathogenesis of IgAN via the ETAR and AT1R, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="ce067110-613a-42d4-b299-2c4712a2ffdf"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2  Pharmacodynamics</title>
                     <text>
                        <paragraph ID="p309013301644375182">Dose-response information is not available. At the recommended dose regimen, no statistically significant exposure-response (E-R) relationship was identified between sparsentan exposure and the percentage reduction from baseline in UPCR at Week 36 over the observed sparsentan exposure range. No clinically meaningful E-R relationships were observed for hypotension of any grade and peripheral edema worst grade. A statistically significant relationship was observed between sparsentan exposures and the incidence of hyperkalemia of any grade.</paragraph>
                        <paragraph ID="p2050224">
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph ID="p1666306861662605054">In a randomized, positive-, and placebo-controlled study in healthy subjects, sparsentan caused QTcF prolongation with maximal mean effect of 8.8 msec (90% CI: 5.9, 11.8) at 800 mg and 8.1 msec (90% CI: 5.2, 11.0) at 1600 mg. The underlying mechanism behind the observed QTc prolongation is unknown but is unlikely to be mediated via direct inhibition of hERG channels. At the recommended dose, no clinically relevant QTc prolongation (i.e., &gt;20 msec) is expected.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="a9170dfb-e72c-4cc8-aed4-aad053d03da7"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3  Pharmacokinetics</title>
                     <text>
                        <paragraph ID="P28">The pharmacokinetics of sparsentan are presented as geometric mean (% coefficient of variation) unless otherwise specified. The C<sub>max</sub> and AUC of sparsentan increase less than proportionally following administration of single doses of 200 mg to 1600 mg. Sparsentan showed time-dependent pharmacokinetics which may be related to the drug inducing its own metabolism over time. Steady-state plasma levels are reached within 7 days with no accumulation of exposure at the approved recommended dosage. Following a single oral dose of 400 mg sparsentan, the mean C<sub>max</sub> and AUC are 7.0 μg/mL and 83.0 μg×h/mL, respectively. Following daily doses of 400 mg sparsentan, the steady-state mean C<sub>max</sub> and AUC are 6.5 μg/mL and 63.6 μg×h/mL, respectively.</paragraph>
                        <paragraph ID="p31089301644375313">
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph ID="p30959301644375322">Following a single oral dose of 400 mg sparsentan, the median (minimum to maximum) time to peak plasma concentration is approximately 3 hours (2 to 8 hours).</paragraph>
                        <paragraph ID="p515110301644375367">
                           <content styleCode="underline">Effect of Food</content>
                        </paragraph>
                        <paragraph ID="p51232301644375376">Sparsentan AUC and C<sub>max</sub> increased by 22% and 108%, respectively, following administration of a single oral 800 mg dose with a high fat, high calorie meal (1000 kcal, 50% fat) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.4">2.4</linkHtml>)]</content>. No clinically significant differences in sparsentan pharmacokinetics were observed following administration of a single 200 mg dose with a high fat, high calorie meal.</paragraph>
                        <paragraph ID="p28420301644375427">
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph ID="p28380301644375433">The apparent volume of distribution at steady state is 61.4 L at the approved recommended dosage.</paragraph>
                        <paragraph ID="p285213301644375440">Sparsentan is &gt;99% bound to human plasma proteins.</paragraph>
                        <paragraph ID="p284814301644375446">
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph ID="p282415301644375474">The clearance of sparsentan is time-dependent which may be related to the drug inducing its own metabolism over time. The apparent clearance (CL/F) of sparsentan is 3.88 L/h following the initial 400 mg dose then increases to 5.11 L/h at steady state.</paragraph>
                        <paragraph ID="p46217301644375483">The half-life of sparsentan is estimated to be 9.6 hours at steady state.</paragraph>
                        <paragraph ID="p97514301644375514">
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph ID="p97647301644375520">Cytochrome P450 3A is the major isozyme responsible for the metabolism of sparsentan.</paragraph>
                        <paragraph ID="p97561301644375493">
                           <content styleCode="underline">Excretion</content>
                        </paragraph>
                        <paragraph ID="p97419301644375501">After a single dose of radiolabeled sparsentan 400 mg to healthy subjects, approximately 80% of the dose was recovered in feces (9% unchanged) and 2% in urine (negligible amount unchanged). 82% of the dosed radioactivity was recovered within a 10-day collection period.</paragraph>
                        <paragraph ID="p120513301644375546">
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph ID="p120574301644375554">No clinically significant differences in the pharmacokinetics of sparsentan were observed based on age (18 – 73 years), sex, race, mild to moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m<sup>2</sup>), or mild to moderate hepatic impairment (Child-Pugh class A or B). Patients with severe hepatic impairment (Child-Pugh class C) and eGFR &lt;30 mL/min/1.73 m<sup>2</sup> have not been studied.</paragraph>
                        <paragraph ID="p122928301644375737">
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph ID="p769336861662605376">Clinical Studies and Model-Informed Approaches</paragraph>
                        <paragraph ID="p769036861662605383">Effect of Other Drugs on Sparsentan</paragraph>
                        <paragraph ID="p747336861662605410">
                           <content styleCode="underline">Strong CYP3A inhibitors:</content> Concomitant use with itraconazole (strong CYP3A inhibitor) increased sparsentan C<sub>max</sub> by 25% and AUC by 174%.</paragraph>
                        <paragraph ID="p747036861662605416">
                           <content styleCode="underline">Moderate CYP3A inhibitors:</content> Concomitant use with cyclosporine (moderate CYP3A inhibitor) increased sparsentan C<sub>max</sub> by 41% and AUC by 70%.</paragraph>
                        <paragraph ID="p7198116861662605425">
                           <content styleCode="underline">Strong CYP3A inducers:</content> Coadministration of rifampin (strong CYP3A inducer) is predicted to decrease sparsentan C<sub>max</sub> by 23% and AUC<sub>0-inf</sub> by 47% at steady state.</paragraph>
                        <paragraph ID="p1615006861662605474">Effect of Sparsentan on Other Drugs</paragraph>
                        <paragraph ID="p1616306861662605489">No clinically significant differences in the pharmacokinetics of midazolam (sensitive CYP3A4 substrate) or pitavastatin (OATP1B1, OATP1B3, P-gp, and BCRP substrate) were observed when co-administered with sparsentan. In addition, sparsentan had no clinically significant effect on serum creatinine levels (an endogenous biomarker of OAT2, OCT2, MATE1, and MATE2K) or on 6β-hydroxycortisol (an endogenous biomarker of OAT3).</paragraph>
                        <paragraph ID="p1616116861662605509">
                           <content styleCode="underline">CYP2B6 substrates:</content> Concomitant use with sparsentan decreased the exposure of bupropion (CYP2B6 substrate) C<sub>max</sub> by 32% and AUC by 33%.</paragraph>
                        <paragraph ID="p130791301644375746">In Vitro Studies</paragraph>
                        <paragraph ID="p770336861662605545">
                           <content styleCode="underline">CYP Enzymes:</content> Sparsentan is a substrate of CYP3A. Sparsentan is both an inhibitor and inducer of CYP3A and an inducer of CYP2B6, CYP2C9, and CYP2C19.</paragraph>
                        <paragraph ID="p770146861662605556">
                           <content styleCode="underline">Transporters:</content> Sparsentan is a substrate of P-gp and BCRP but is not a substrate of OATP1B1 or OATP1B3. Sparsentan is an inhibitor of P-gp, BCRP, OATP1B3, and OAT3 but does not inhibit MRP, OATP1B1, NTCP, OCT2, OAT1, MATE1, or MATE2K at relevant concentrations.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="93990ae5-56e0-40f1-985b-58d0ac71a02d"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13  NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250401"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="33594a45-300d-4b70-a4f2-61379d4c5c83"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1  Carcinogenesis, Mutagenesis, and Impairment of Fertility</title>
                     <text>
                        <paragraph ID="P30">
                           <content styleCode="italics">Carcinogenesis</content>: In the two-year rat carcinogenicity study, there was no evidence of increased incidence of neoplasia in male rats orally administered at 15 mg/kg/day (the only dose evaluated) and in female rats orally administered up to 240 mg/kg/day, which provided an exposure approximately 0.7 times and 26 times the AUC at the MRHD, respectively. In the 26-week transgenic mouse study, there was no evidence of increased incidence of neoplasia in male and female mice orally administered sparsentan at doses up to 600 mg/kg/day.</paragraph>
                        <paragraph ID="p360611301644376244">
                           <content styleCode="italics">Mutagenesis</content>: There was no evidence of mutagenicity or clastogenicity for sparsentan in in vitro bacteria reverse mutation and chromosomal aberration assays, or in an in vivo rat micronucleus study.</paragraph>
                        <paragraph ID="p133531301644376249">
                           <content styleCode="italics">Impairment of fertility</content>: In a fertility and early embryonic development study in rats, oral administration of sparsentan at doses of 20, 80, and 320 mg/kg/day for at least 36 (females) and 49 (males) days did not result in any adverse effects on estrous cycles, mating, fertility, sperm evaluation, or pregnancy incidence at doses up to 320 mg/kg/day, which provided approximately 10 and 14 times the AUC at the MRHD for males and females, respectively. Male reproductive organ toxicity was not evident in chronic toxicity studies with sparsentan at exposures up to 10 times and 1.3 times the AUC at the MRHD in rats and monkeys, respectively. </paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="7b31d057-d78c-47dd-870f-3fc1e5472f01"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14  CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="P32">
                     <content>The effect of FILSPARI on proteinuria and kidney function (estimated glomerular filtration rate, eGFR) was assessed in a randomized, double-blind, active-controlled, multicenter, global study</content>
                     <content> (PROTECT, </content>
                     <linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT03762850">NCT03762850</linkHtml>
                     <content>) in adults with biopsy-proven primary IgAN, eGFR ≥30 mL/min/1.73 m<sup>2</sup>, and total urine protein ≥1.0 g/day on a stable dose of maximally-tolerated RAS inhibitor treatment. Patients with chronic kidney disease due to another condition in addition to IgAN or those who had been recently treated with systemic immunosuppressants were excluded.</content>
                  </paragraph>
                  <paragraph>Patients were randomized (1:1) to either FILSPARI (400 mg once daily following 200 mg once daily for 14 days) or irbesartan (300 mg once daily following 150 mg once daily for 14 days). Rescue immunosuppressive treatment could be initiated per investigator discretion during the trial. Concomitant use of sodium-glucose cotransporter-2 (SGLT2) inhibitors, other RAS inhibitors, and aldosterone blockers were prohibited.</paragraph>
                  <paragraph>The primary efficacy endpoint for the interim analysis was the change from baseline in urine protein/creatinine ratio (UPCR) at Week 36 based on the first 281 randomized patients who had reached the Week 36 visit. The key secondary efficacy endpoint for the final analysis was the rate of change in eGFR over a 110-week period following initiation of randomized therapy.</paragraph>
                  <paragraph>The 404 patients who enrolled and received study medication had a mean age of 46 years (range 18 to 76 years); 70% were male, 67% White, 28% Asian, and 1% Black or African American. Approximately 78% had a history of hypertension, 11% had diabetes or impaired fasting glucose, and 56% had hematuria based on urine dipstick. At baseline, the mean eGFR was 57 mL/min/1.73 m<sup>2</sup>, the geometric mean UPCR was 1.2 g/g, and 49 (12%) patients had proteinuria &gt;3.5 g/24 hours.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Urine Protein/Creatinine Ratio (UPCR)</content>
                  </paragraph>
                  <paragraph>
                     <br/>
                     <content>The trial met the prespecified primary endpoint of relative change from baseline in UPCR at Week 36 based on an interim analysis of 281 randomized patients who had reached the Week 36 visit. The interim analysis showed a 45% decrease in UPCR at Week 36 relative to baseline for patients treated with FILSPARI compared to a 15% decrease for patients treated with irbesartan resulting in a 35% reduction in the ratio of mean UPCR (95% CI: 23% to 45% reduction; p&lt;0.0001). In the final analysis of 404 randomized patients, the treatment effects in UPCR observed at Week 36 and Week 110 were consistent with the results obtained at the interim analysis. The mean percent change from baseline over the course of the double-blind period is displayed in Figure 1.</content>
                  </paragraph>
                  <table ID="t79736686" width="100%">
                     <caption>Figure 1: Geometric Mean Percent Change from Baseline in Urine Protein-to-Creatinine Ratio by Visit through Week 110 (PROTECT, FAS)</caption>
                     <colgroup>
                        <col/>
                     </colgroup>
                     <tfoot>
                        <tr styleCode="First FIRST Last LAST">
                           <td>Adjusted GMPC of UPCR was based on MMRM stratified by screening eGFR and total urine protein excretion. MMRM analysis includes UPCR data during the double-blind period up to week 110 regardless of treatment discontinuation or Immunosuppressive therapy initiation. Missing data were imputed using multiple imputation under assumptions of missing at random and missing not at random depending on the patient’s intercurrent event status. Baseline was defined as the last non-missing observation on or prior to the start of dosing. Counts in axis table represent number of subjects with observed UPCR data by visit and treatment group. BL=baseline; CI=Confidence Interval; FAS=Full Analysis Set; GMPC=geometric mean percent change; LS=least squares; MMRM=mixed-model repeated measures; N= number of subjects with available data at the time of analysis; UPCR=Urine protein/creatinine ratio.</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="First FIRST Last LAST">
                           <td>
                              <paragraph>
                                 <renderMultiMedia referencedObject="g13079319571664232091"/>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Estimated Glomerular Filtration Rate (eGFR)</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>In the final analysis of 404 randomized patients, FILSPARI reduced the rate of decline in kidney function from baseline to Week 110 compared to irbesartan. The mean eGFR slope from baseline to Week 110 was -3.0 mL/min/1.73 m<sup>2</sup> per year for FILSPARI and -4.2 mL/min/1.73 m<sup>2</sup> per year for irbesartan, corresponding to a treatment effect of 1.2 mL/min/1.73 m<sup>2</sup> per year (95 %CI: 0.2 to 2.1; p=0.0168). The mean change from baseline in eGFR during the double-blind period is shown in Figure 2. The treatment effect on the rate of change in eGFR through Week 110 was generally consistent across key subgroups, including key demographic (such as age, sex, race, ethnicity, and region) and baseline disease (such as baseline BMI and baseline proteinuria) characteristics. The treatment benefit with FILSPARI on the rate of change in eGFR through Week 110 was not evident in patients with an eGFR ≥90 mL/min/1.73 m<sup>2</sup>; however, there was a small number of patients in this subgroup.</paragraph>
                  <table width="100%">
                     <caption>Figure 2: Absolute Change in eGFR (mL/min/1.73 m<sup>2</sup>) by Visit (FAS) </caption>
                     <tfoot>
                        <tr styleCode="First Last">
                           <td>*eGFR was calculated using the CKD-EPI equation. Baseline was defined as the last non-missing observation on or prior to the start of dosing. The analysis includes eGFR data during the double-blind period up to Week 110 regardless of treatment discontinuation or immunosuppressive therapy initiation. Rescue immunosuppressive treatment for IgAN was initiated in 7 (3%) and 18 (9%) patients in the FILSPARI and irbesartan group respectively. BL=baseline; CI=confidence interval; CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration; eGFR=estimated glomerular filtration rate; FAS=Full Analysis Set; IgAN=immunoglobulin A nephropathy; LS=least squares; N=number of subjects with available data at the time of analysis.</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="First Last">
                           <td>
                              <br/>
                              <renderMultiMedia referencedObject="Le76f1b35-1ec8-4519-89c6-30626ceffc10"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="g13079319571664232091">
                     <text>Figure 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="figure_1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Le76f1b35-1ec8-4519-89c6-30626ceffc10">
                     <text>Figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure_2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="6e664621-021b-4343-bd68-b8d43b764ec7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16  HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="P34">FILSPARI is supplied in bottles of 30 film-coated tablets.</paragraph>
                  <list listType="unordered" ID="l15496301644377137" styleCode="Disc">
                     <item>200 mg tablets are film-coated, modified oval, white to off-white, debossed with “105” on one side and plain on the other side, available in bottles of 30 tablets with child-resistant caps (NDC 68974-200-30).</item>
                     <item>400 mg tablets are film-coated, modified oval, white to off-white, debossed with “021” on one side and plain on the other side, available in bottles of 30 tablets with child-resistant caps (NDC 68974-400-30).</item>
                  </list>
                  <paragraph ID="p155513301644377159">
                     <content styleCode="bold">Storage</content>
                  </paragraph>
                  <paragraph ID="p138604301644377166">Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store FILSPARI in its original container.</paragraph>
               </text>
               <effectiveTime value="20250401"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="18ad94bf-f1a0-4963-b754-4371a3ff035b"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17  PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="P35">
                     <content styleCode="bold">Advise patients to read the FDA-approved patient labeling (Medication Guide).</content>
                  </paragraph>
                  <paragraph ID="p1386510301644377195">
                     <content styleCode="bold">Restricted access</content>
                  </paragraph>
                  <paragraph>Advise the patient that FILSPARI is only available through a restricted access program called the FILSPARI REMS.</paragraph>
                  <paragraph ID="p36216301644377205">As a component of the FILSPARI REMS, prescribers must review the contents of the FILSPARI Medication Guide with the patient before initiating FILSPARI.</paragraph>
                  <paragraph ID="p140913301644377255">Instruct patients that the risks associated with FILSPARI include:</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity</content>
                  </paragraph>
                  <paragraph>Advise patients with symptoms suggesting hepatotoxicity (nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, or itching) to immediately stop taking FILSPARI and seek medical attention <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_2.3">2.3</linkHtml>, <linkHtml href="#Section_2.5">2.5</linkHtml>), Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p140963301644377264">
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Educate and counsel patients who can become pregnant about the need to use reliable methods of contraception prior to treatment with FILSPARI, during treatment and for one month after treatment discontinuation. Patients who can become pregnant must have pregnancy tests prior to treatment with FILSPARI, monthly during treatment, and one month after treatment discontinuation<content styleCode="italics"> [see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_2.3">2.3</linkHtml>), Contraindications (<linkHtml href="#Section_4">4</linkHtml>), Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>), Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.3">8.3</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p141073301644377311">Patients should be instructed to immediately contact their physician if they suspect they may be pregnant. Patients should seek additional contraceptive advice from a gynecologist or similar expert as needed.</paragraph>
                  <paragraph ID="p924776861662608915">Educate and counsel patients who can become pregnant on the use of emergency contraception in the event of unprotected sex or contraceptive failure.</paragraph>
                  <paragraph>Advise patients to contact their gynecologist or healthcare provider if they want to change the form of birth control which is used to ensure that another acceptable form of birth control is selected.</paragraph>
                  <paragraph>Advise the patient that FILSPARI is available only from certified pharmacies that are enrolled in the FILSPARI REMS.</paragraph>
                  <paragraph>Patients must sign the FILSPARI REMS Patient Enrollment Form to confirm that they understand the risks of FILSPARI.</paragraph>
                  <paragraph ID="p898056861662608948">
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph ID="p897536861662608958">Advise patients not to breastfeed during treatment with FILSPARI <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#Section_8.2">8.2</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p896436861662608995">
                     <content styleCode="underline">Drug Interactions</content>
                  </paragraph>
                  <paragraph ID="p875336861662609003">Advise patients to inform their healthcare provider of all concomitant medications, including prescription medications, over-the-counter drugs, vitamins/supplements, herbal products, and grapefruit <content styleCode="italics">[see Contraindications (<linkHtml href="#Section_4">4</linkHtml>), Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>, <linkHtml href="#Section_5.5">5.5</linkHtml>, <linkHtml href="#Section_5.6">5.6</linkHtml>, <linkHtml href="#Section_5.7">5.7</linkHtml>), Drug Interactions (<linkHtml href="#Section_7">7</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p1025246861662609088">
                     <content styleCode="underline">Other Risks Associated with FILSPARI</content>
                  </paragraph>
                  <paragraph ID="p1024736861662609124">Inform patients of other risks associated with FILSPARI, including:</paragraph>
                  <list listType="unordered" ID="l1024236861662609131" styleCode="Disc">
                     <item>Hypotension: Advise patients to remain hydrated <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)].</content>
                     </item>
                     <item>Hyperkalemia: Advise patients not to use potassium supplements or salt substitutes that contain potassium without consulting their healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.6">5.6</linkHtml>)].</content>
                     </item>
                  </list>
                  <paragraph ID="p154074301644377726">
                     <content styleCode="underline">Dosing</content>
                  </paragraph>
                  <paragraph ID="p1716716861662609177">Advise patients to take the full daily dose with water prior to the morning or evening meal. Maintain the same dosing pattern in relationship to meals. If a dose is missed, take the next dose at the regularly scheduled time. Do not take double or extra doses <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.4">2.4</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p9229119571664230991"/>
                  <paragraph ID="p156182301644377758">Distributed by Travere Therapeutics, Inc., San Diego, CA 92130</paragraph>
                  <paragraph ID="p156212301644377764">FILSPARI is a registered trademark of Travere Therapeutics, Inc.</paragraph>
               </text>
               <effectiveTime value="20250401"/>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="54fc56bd-59dc-4204-9812-1639e85b573b"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table ID="medguide">
                     <colgroup>
                        <col width="4*"/>
                        <col width="46*"/>
                        <col width="49*"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" colspan="3" align="center">
                              <content styleCode="bold">Medication Guide</content>
                              <br/>
                              <content styleCode="bold">FILSPARI<sup>®</sup> (fil spah ree)</content>
                              <br/>
                              <content styleCode="bold">(sparsentan)</content>
                              <br/>
                              <content styleCode="bold">tablets</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" colspan="3">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about FILSPARI?</content>
                              </paragraph>
                              <paragraph>FILSPARI is only available through the FILSPARI REMS Program. Before you begin treatment with FILSPARI, you must read and agree to all of the instructions in the FILSPARI REMS Program.</paragraph>
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">FILSPARI can cause serious side effects, including:</content>
                              </paragraph>
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">Liver problems.</content>
                              </paragraph>
                              <paragraph/>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">FILSPARI can cause changes in liver tests.</content> Liver failure was not observed in people treated with FILSPARI in clinical studies, but some medicines that are like FILSPARI can cause liver failure. Your healthcare provider will do blood tests to check your liver before starting treatment with FILSPARI, monthly for the first 12 months, then every 3 months during treatment. Your healthcare provider may temporarily stop or permanently stop treatment with FILSPARI if you have changes in your liver tests.<br/>Stop taking FILSPARI and get medical help right away if you develop any of the following signs of liver problems during treatment with FILSPARI:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" ID="l5811452111530026187" styleCode="Circle">
                                 <item>nausea or vomiting</item>
                                 <item>pain on the upper right side of your stomach area</item>
                                 <item>tiredness</item>
                                 <item>loss of appetite</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" ID="l5838212111530026738" styleCode="Circle">
                                 <item>yellowing of your skin or the white part of your eyes (jaundice)</item>
                                 <item>dark “tea-colored” urine</item>
                                 <item>fever</item>
                                 <item>itching</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">Serious birth defects.</content>
                              </paragraph>
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">FILSPARI can cause serious birth defects if taken during pregnancy.</content>
                              </paragraph>
                              <paragraph/>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Patients who can become pregnant must not be pregnant when they start taking FILSPARI or become pregnant during treatment with FILSPARI or for 1 month after stopping treatment with FILSPARI.</content>
                                 </item>
                                 <item>Patients who can become pregnant must have a negative pregnancy test before starting FILSPARI and must have a monthly negative pregnancy test during treatment and 1 month after stopping treatment with FILSPARI.<list listType="unordered" ID="l78895112112530028646" styleCode="Circle">
                                       <item>Patients who can become pregnant are those who:<list listType="unordered" ID="l5841522111530030779" styleCode="Square">
                                             <item>have entered puberty, even if they have not started their menstrual period, <content styleCode="bold">and</content>
                                             </item>
                                             <item>have a uterus, <content styleCode="bold">and</content>
                                             </item>
                                             <item>have not gone through menopause. Menopause means that you have not had a menstrual period for at least 12 months for natural reasons, or that you have had your ovaries removed.</item>
                                          </list>
                                       </item>
                                       <item>Patients who cannot become pregnant are those who:<list listType="unordered" ID="l5951525751110030427" styleCode="Square">
                                             <item>have not yet entered puberty, <content styleCode="bold">or</content>
                                             </item>
                                             <item>do not have a uterus, <content styleCode="bold">or</content>
                                             </item>
                                             <item>have gone through menopause. Menopause means that you have not had a menstrual period for at least 12 months for natural reasons, or that you have had your ovaries removed, <content styleCode="bold">or</content>
                                             </item>
                                             <item>are infertile for any other medical reason and this infertility is permanent and cannot be reversed.</item>
                                          </list>
                                       </item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Patients who can become pregnant must use effective birth control before starting treatment with FILSPARI, during treatment with FILSPARI, and for 1 month after stopping FILSPARI because the medicine may still be in your body.</content>
                              </paragraph>
                              <paragraph/>
                              <list listType="unordered">
                                 <item>If you have had a tubal sterilization or have an IUD (intrauterine device) or progesterone implant, these methods may be used alone, and no other form of birth control is needed.</item>
                                 <item>Talk with your healthcare provider or gynecologist (a healthcare provider who specializes in reproduction) to find out about options for effective forms of birth control that you may use to prevent pregnancy during treatment with FILSPARI.</item>
                                 <item>If you decide that you want to change the form of birth control that you use, talk with your healthcare provider or gynecologist to be sure that you choose another effective form of birth control.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">See the chart below for acceptable birth control options during treatment with FILSPARI.</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="g174341301661897006"/>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Do not have unprotected sex.</content> Talk to your healthcare provider or pharmacist right away if you have unprotected sex or if you think your birth control has failed. Your healthcare provider may talk with you about using emergency birth control.</item>
                                 <item>
                                    <content styleCode="bold">Tell your healthcare provider right away if you miss a menstrual period or think you may be pregnant.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" colspan="3">
                              <paragraph>
                                 <content styleCode="bold">What is FILSPARI?</content>
                              </paragraph>
                              <paragraph>FILSPARI is a prescription medicine used to slow kidney function decline in adults with a kidney disease called primary immunoglobulin A nephropathy (IgAN), who are at risk for their disease getting worse.</paragraph>
                              <paragraph/>
                              <paragraph>It is not known if FILSPARI is safe and effective in children.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" colspan="3">
                              <paragraph>
                                 <content styleCode="bold">Do not take FILSPARI if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">are pregnant, plan to become pregnant, or become pregnant during treatment with FILSPARI. FILSPARI can cause serious birth defects. (</content>See<content styleCode="bold"> “What is the most important information I should know about FILSPARI?”)</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">are taking any of these medicines:</content>
                                    <list listType="unordered" ID="l5951522709530035429" styleCode="Circle">
                                       <item>an angiotensin receptor blocker, or</item>
                                       <item>an endothelin receptor antagonist, or</item>
                                       <item>aliskiren.</item>
                                    </list>
                                 </item>
                              </list>Ask your healthcare provider or pharmacist if you are not sure if you take one of these medicines.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" colspan="3">
                              <paragraph>
                                 <content styleCode="bold">Before taking FILSPARI, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>have liver problems</item>
                                 <item>are pregnant or plan to become pregnant during treatment with FILSPARI. FILSPARI can cause serious birth defects. See “<content styleCode="bold">What is the most important information I should know about FILSPARI?</content>”</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if FILSPARI passes into your breast milk. Do not breastfeed during treatment with FILSPARI. Talk to your healthcare provider about the best way to feed your baby during treatment with FILSPARI.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, herbal supplements, and grapefruit. FILSPARI and other medicines may affect each other and cause side effects. Do not start any new medicine until you check with your healthcare provider.</paragraph>
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">Especially tell your healthcare provider if you take:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>nonsteroidal anti-inflammatory drugs (NSAIDs)</item>
                                 <item>potassium-containing medicines, potassium supplements, or salt substitutes containing potassium</item>
                                 <item>blood pressure medicines</item>
                                 <item>H2 receptor blocker medicine or proton pump inhibitor (PPI) medicine</item>
                              </list>Ask your healthcare provider or pharmacist if you are not sure if you take one of these medicines.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" colspan="3">
                              <paragraph>
                                 <content styleCode="bold">How should I take FILSPARI?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>FILSPARI will be provided to you by a certified pharmacy. Your healthcare provider will give you complete details.</item>
                                 <item>Take FILSPARI exactly as your healthcare provider tells you to take it. Do not stop taking FILSPARI unless your healthcare provider tells you.</item>
                                 <item>Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with FILSPARI if you develop side effects.</item>
                                 <item>Take FILSPARI whole with water before your morning or evening meal. Take your dose before the same meal each day.</item>
                                 <item>If you miss a dose, take the next dose at the regularly scheduled time. Do not take 2 doses at the same time or take extra doses.</item>
                                 <item>If you take an antacid, take FILSPARI 2 hours before or 2 hours after you take your antacid.</item>
                                 <item>If you take too much FILSPARI, call your healthcare provider or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" colspan="3">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of FILSPARI?</content>
                              </paragraph>
                              <paragraph>FILSPARI can cause serious side effects, including:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Liver problems.</content> See “<content styleCode="bold">What is the most important information I should know about FILSPARI?</content>”</item>
                                 <item>
                                    <content styleCode="bold">Serious birth defects.</content> See “<content styleCode="bold">What is the most important information I should know about FILSPARI?</content>”</item>
                                 <item>
                                    <content styleCode="bold">Low blood pressure.</content> Low blood pressure is common during treatment with FILSPARI and can also be serious. Tell your healthcare provider if you feel dizzy, light-headed, or faint. Stay hydrated during treatment with FILSPARI.</item>
                                 <item>
                                    <content styleCode="bold">Worsening of kidney function.</content> Your healthcare provider will check your kidney function during treatment with FILSPARI.</item>
                                 <item>
                                    <content styleCode="bold">Increased potassium in your blood.</content> This is common during treatment with FILSPARI and can also be serious. Your healthcare provider will check your potassium blood level during treatment with FILSPARI.</item>
                                 <item>
                                    <content styleCode="bold">Fluid retention.</content> FILSPARI can cause your body to hold too much water. Tell your healthcare provider right away if you have any unusual weight gain or swelling of your ankles or legs.</item>
                              </list>The most common side effects of FILSPARI include:</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" ID="l5851852111830226187">
                                 <item>swelling of hands, legs, ankles and feet (peripheral edema)</item>
                                 <item>dizziness</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" ID="l4832212111530016538">
                                 <item>low red blood cells (anemia)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <paragraph/>
                              <paragraph>These are not all the possible side effects of FILSPARI.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" colspan="3">
                              <paragraph>
                                 <content styleCode="bold">How should I store FILSPARI?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Store FILSPARI at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>Store FILSPARI in the original container.</item>
                                 <item>The bottle has a child-resistant closure.</item>
                              </list>
                              <content styleCode="bold">Keep FILSPARI and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" colspan="3">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of FILSPARI.</content>
                              </paragraph>Medicines are sometimes prescribed for purposes other than those listed in the Medication Guide. Do not use FILSPARI for a condition for which it was not prescribed. Do not give FILSPARI to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about FILSPARI that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" colspan="3">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in FILSPARI?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content> sparsentan</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content> colloidal silicon dioxide, lactose anhydrous, magnesium stearate, silicified microcrystalline cellulose, and sodium starch glycolate. Tablets are film coated with material containing macrogol/polyethylene glycol, polyvinyl alcohol-partially hydrolyzed, talc, and titanium dioxide.</paragraph>
                              <paragraph/>
                              <paragraph>Distributed by Travere Therapeutics, Inc., San Diego, CA 92130<br/>FILSPARI is a registered trademark of Travere Therapeutics, Inc.<br/>For more information, go to www.FILSPARI.com or call 1-877-659-5518.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule" colspan="3"/>
                        </tr>
                        <tr>
                           <td colspan="2">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right">Revised: September 2024</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="g174341301661897006">
                     <text>Effective Birth Control Options</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="birth_control_options.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L78cf6b73-3a6c-4088-b0bd-2fd1382dd23d">
               <id root="71075f57-dd6c-40a7-875e-9db347e334ac"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 68974-200-30<br/>30 Tablets</paragraph>
                  <paragraph>FILSPARI™<br/>(sparsentan) tablets</paragraph>
                  <paragraph>200 mg</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Manufactured for:<br/>Travere Therapeutics, Inc.,<br/>San Diego, CA 92130</paragraph>
                  <paragraph>Manufactured by:<br/>Catalent<br/>Kansas City, MO 64137</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="La8114e41-328c-42c1-b45b-ec31aca2f069"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="La8114e41-328c-42c1-b45b-ec31aca2f069">
                     <text>PRINCIPAL DISPLAY PANEL - 200 mg Tablet Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="filspari-200mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="La7dbd9bf-f25c-4400-b751-0c95eaad8f2e">
               <id root="553637af-d46a-4c9f-a473-c6fdc18fdf4f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 400 mg Tablet Label</title>
               <text>
                  <paragraph>NDC 68974-400-30<br/>30 Tablets</paragraph>
                  <paragraph>FILSPARI™<br/>(sparsentan) tablets</paragraph>
                  <paragraph>400 mg</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Manufactured for:<br/>Travere Therapeutics, Inc.,<br/>San Diego, CA 92130</paragraph>
                  <paragraph>Manufactured by:<br/>Catalent<br/>Kansas City, MO 64137</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lccb560f0-0271-42a2-bae5-1301ccb525cb"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="Lccb560f0-0271-42a2-bae5-1301ccb525cb">
                     <text>PRINCIPAL DISPLAY PANEL - 400 mg Tablet Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="filspari-400mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>